Compare LW & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LW | BLCO |
|---|---|---|
| Founded | 1950 | 1853 |
| Country | United States | Canada |
| Employees | 10100 | N/A |
| Industry | Packaged Foods | Ophthalmic Goods |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | 2016 | 2022 |
| Metric | LW | BLCO |
|---|---|---|
| Price | $42.18 | $15.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $53.00 | $18.55 |
| AVG Volume (30 Days) | ★ 2.5M | 392.7K |
| Earning Date | 04-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $4.30 | $8.63 |
| Revenue Next Year | N/A | $5.58 |
| P/E Ratio | $45.37 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $39.60 | $10.45 |
| 52 Week High | $67.07 | $18.92 |
| Indicator | LW | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 43.36 |
| Support Level | $41.41 | $14.39 |
| Resistance Level | $57.57 | $17.66 |
| Average True Range (ATR) | 1.40 | 0.50 |
| MACD | 0.17 | -0.08 |
| Stochastic Oscillator | 64.64 | 37.85 |
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.